Every 10-Q that REVIVA PHARMA HLDGS INC (RVPH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RVPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVPH filings page.
Reviva Pharmaceuticals Holdings, Inc. reported unaudited results for the quarter ended June 30, 2026. Cash and cash equivalents were $19.9 million, up from $14.4 million at December 31, 2025, and working capital surplus was $15.2 million. Total assets were $21.1 million.
The company generated no product revenue and recorded a net loss of $2.4 million for the quarter and $5.6 million for the first half of 2026, narrower than the prior-year periods, driven by sharply lower research and development expenses (down to $1.4 million from $3.7 million in the quarter) as its RECOVER-1 open-label extension study wound down, and reduced general and administrative costs.
Reviva raised capital through a March 2026 public offering, which delivered net proceeds of about $8.9 million, and an at-the-market program that added approximately $2.5 million in the first half, and it has significant warrant overhang. Management believes existing cash can fund operations into July 2027, yet explicitly states that cash on hand is not sufficient for 12 months from issuance and discloses substantial doubt about its ability to continue as a going concern without additional financing. During the period, the company completed a 1-for-20 reverse stock split and its common stock was delisted from Nasdaq and is now quoted on the OTCQB Venture Market.
Reviva Pharmaceuticals Holdings, Inc. reported a narrower net loss of about $3.2 million for the three months ended March 31, 2026, compared with $6.4 million a year earlier, mainly due to sharply lower research and development spending. R&D expenses fell to roughly $1.4 million from $4.1 million, and general and administrative costs declined to about $1.8 million from $2.4 million.
Cash and cash equivalents increased to $22.2 million as of March 31, 2026, driven by financing activities, including a March 2026 public offering with $10.0 million in gross proceeds and an at-the-market equity program that raised about $2.5 million. Working capital surplus rose to approximately $17.4 million, and total stockholders’ equity more than doubled to about $17.4 million.
The company remains a clinical-stage biotech with no product revenue and an accumulated deficit of roughly $187.3 million. Management states that existing cash is expected to fund operations into early 2027 but explicitly concludes there is substantial doubt about Reviva’s ability to continue as a going concern without additional capital. During the quarter, Reviva also effected a 1‑for‑20 reverse stock split and later received notice that its shares will be delisted from Nasdaq and quoted on the OTCQB Venture Market under “RVPH.”
Reviva Pharmaceuticals (RVPH) filed its Q3 2025 10‑Q, reporting a narrower net loss and added capital from recent offerings. Net loss was $4.0 million for the quarter (vs. $8.4 million a year ago) and $16.5 million for the nine months (vs. $23.7 million). Operating expenses declined sharply as R&D fell to $2.1 million and G&A to $1.9 million in Q3.
Cash and cash equivalents were $13.2 million with total assets of $14.3 million and current liabilities of $9.7 million. Stockholders’ equity improved to $4.5 million. The company completed a June 2025 offering (20.0M shares with Series C/D warrants; gross $10.0M, net about $9.0M) and a September 2025 offering (27.0M shares with Series E/F warrants; gross $9.0M, net about $8.1M). It also sold 2.45M shares via its ATM for roughly $1.2M net.
The company disclosed substantial doubt about its ability to continue as a going concern. Subsequent to quarter‑end, warrant exercises in October–November 2025 added 18.7M shares for approximately $6.4M gross. Shares outstanding were 96,337,119 as of September 30, 2025, and 115,058,619 as of November 11, 2025.